by 
Shigellosis, commonly known as bacillary dysentery, is caused by Shigella bacteria and it leads to diarrhea, fever, and stomach cramps starting a day or two after exposure to the bacteria. There are four subgroups of Shigella—Shigella dysenteriae, Shigella flexneri, Shigella boydii, and Shigella sonnei. Shigella vaccines are used to prevent infections caused by Shigella bacteria. The global shigella vaccines market consists of various pipelines vaccines in different clinical development phases such as phase 1, phase 2 and phase 3. Some of the key players operating in this market are developing conjugate Shigella vaccines which provide long lasting immunity.
The global Shigella Vaccines Market is estimated to be valued at US$ 574.20 mn in 2023 and is expected to exhibit a CAGR of 6.4% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics: Increasing funding by governments and private organizations for the development of novel Shigella vaccines is expected to drive the market growth over the forecast period. For instance, the Bill and Melinda Gates Foundation granted funding of US$ 8.5 million to the International Vaccine Institute (IVI) to support the development of a low-cost Shigella conjugate vaccine. Another major driver for this market is the rising global incidence of shigellosis. According to the World Health Organization (WHO), shigellosis causes over 100,000 deaths each year, especially in low- and middle-income countries. Furthermore, the growing initiatives by governments and non-profit organizations for immunization programs in developing countries will also aid in market expansion. However, high costs associated with vaccine development and approval procedures may restrain the market growth.
Segment Analysis
The global Shigella Vaccines market is dominated by the pediatric segment. Shigellosis or shiga toxin-producing Escherichia coli (STEC) infection is highly prevalent in children aged between 6-59 months. According to WHO, children of this age group account for over 50% of shigellosis cases globally. The disease can cause high fever, bloody diarrhea and dehydration in children and lead to death if not treated on time. Hence, development of an effective vaccine for Shigella is critical to protect children in endemic regions.
PEST Analysis
Political: Major government initiatives are being taken up in developing countries to control gastrointestinal infections through vaccination programs. Funding is being provided for research and development of affordable Shigella vaccines.
Economic: The economic burden of Shigella infection is quite high, especially in low and middle-income countries where it impacts work productivity and wage earnings. Successful development of vaccines can reduce this burden substantially.
Social: High prevalence of Shigella infections in densely populated regions and among marginalized communities has created an urgent need for prevention. Widespread acceptability of vaccination can help curb the disease.
Technological: Advancements in vaccine production technologies have enabled development of candidate vaccines using modern approaches like live-attenuated and subunit vaccine development which induce strong immune responses.
Key Takeaways
The global Shigella Vaccines market is expected to witness high growth over the forecast period till 2030.
Regional Analysis: North America currently dominates the market due to large healthcare investments and regional presence of key players. However, Asia Pacific is poised to be the fastest growing market due to the rising incidence of Shigella infections in densely populated developing nations of India and China.
The key players operating in the Shigella Vaccines market are MSD Wellcome Trust Hilleman Laboratories Pvt. Ltd., Novartis (Novartis Vaccines Institute for Global Health), and GlaxoSmithKline plc. MSD Wellcome Trust Hilleman Laboratories Pvt. Ltd. is conducting phase 1 and 2 clinical trials of its oral live-attenuated Shigella vaccination candidate to evaluate its safety and efficacy. Novartis is developing a vaccine based on live-attenuated Shigella strains aimed at high-burden countries. GlaxoSmithKline’s candidate targets the most common serotypes Shigella flexneri 2a and 3a using an innovative antigen delivery system.
*Note:
- Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
